# EDGAR Filing Document

**Accession Number:** 0001091596
**File Stem:** 0001437749-26-019244
**Filing Date:** 2026-6
**Character Count:** 7285
**Document Hash:** f09dab2aa2504f2e783c6e10b96fe165
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-019244.hdr.sgml**: 20260602

**ACCESSION NUMBER**: 0001437749-26-019244

**CONFORMED SUBMISSION TYPE**: 4/A

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260123

**FILED AS OF DATE**: 20260602

**DATE AS OF CHANGE**: 20260602

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Pittman Scott M.
- **CENTRAL INDEX KEY:** 0001674752

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32518
- **FILM NUMBER:** 261058722

**MAIL ADDRESS:**
- **STREET 1:** 3683 JOHN NASH BLVD.
- **CITY:** BLUEFIELD
- **STATE:** WV
- **ZIP:** 24701
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nuo Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001091596
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 233011702
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 8285 EL RIO
- **STREET 2:** SUITE 190
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77054
- **BUSINESS PHONE:** 832-236-9060

**MAIL ADDRESS:**
- **STREET 1:** 8285 EL RIO
- **STREET 2:** SUITE 190
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77054

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Nuo Therapeutics, Inc
- **DATE OF NAME CHANGE:** 20141112

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CYTOMEDIX INC
- **DATE OF NAME CHANGE:** 20000511

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AUTOLOGOUS WOUND THERAPY INC
- **DATE OF NAME CHANGE:** 20000407

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4/A

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Pittman Scott M.<br><sub>(Last) (First) (Middle)</sub><br>C/O NUO THERAPEUTICS, INC.<br>8285 EL RIO, SUITE190<br><sub>(Street)</sub><br>HOUSTON, TX 77054<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-01-23 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Nuo Therapeutics, Inc. [ AURX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Initial Warrant (right to buy)<sup>(1)</sup> | $1.50 | 2026-01-23 |  | A |  | 30050 |  | 2026-01-23 | 2031-01-23 | Common Stock | 30050 | $1.50 | 30050<sup>(1)</sup> | D |  |
| Second Warrant (right to buy)<sup>(2)</sup> | $1.50 | 2026-01-23 |  | A |  | 36750 |  | 2026-09-30<sup>(3)</sup> | 2031-01-23 | Common Stock | 36750 | $1.50 | 0 | D |  |
| Prepayment Warrant (right to buy) | $1.50 | 2026-01-23 |  | A |  | 7516<sup>(4)</sup> |  | 2026-01-23<sup>(5)</sup> | 2031-01-23 | Common Stock | 7516<sup>(4)</sup> | $1.50 | 0 | D |  |

---

### Footnotes:

(1) This Form 4 amendment corrects the name of warrant issued in the form of an integrated Initial Warrant, which represents Commitment Initial, Origination Initial, and Capital Initial Warrants immediately exercisable for an aggregate of 30,050 shares of Common Stock.

(2) This Form 4 amendment corrects the name of warrant issued in the form of an integrated Second Warrant, which represents Origination Second Capital Second Warrants.

(3) Will vest (if at all) on September 30, 2026 provided a Second Funding occurs in accordance with the Loan and Security Agreement dated January 21, 2026 among the Issuer, the Reporting Person, and other parties thereto (the "Loan Agreement").

(4) Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement.

(5) Will vest (if at all) upon the occurrence of a Prepayment, but no later than December 31, 2028, in accordance with the Loan Agreement.

**Signature:** /s/ David Jorden, attorney-in-fact  
**Date:** 2026-06-02

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**